fulltext.pdf 279 KB
Murakami, Jun Okayama University
Asaumi, Jun-ichi Okayama University
Maki, Yuu Okayama University
Tsujigiwa, Hidetsugu Okayama University
Kuroda, Masahiro Okayama University
Nagai, Noriyuki Okayama University
Yanagi, Yoshinobu Okayama University
Inoue, Tetsuyoshi Okayama University
Kawasaki, Shoji Okayama University
Tanaka, Noriaki Okayama University
Matsubara, Nagahide Okayama University
Kishi, Kanji Okayama University
Maspin, which belongs to the serine protease inhibitor (serpin) superfamily, has been proposed as a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis. In the present study, we examined the effects of 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, and FR901228, a histone deacetylase (HDAC) inhibitor, on maspin expression in oral cancer cell tines. The expression levels of maspin mRNA were divided into two groups, which was the maspin tow-expressed and high-expressed cell lines in the 12 oral cancer cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines. Moreover, the methylation status was not altered after 5-aza-dC treatment. However, the transcription of the maspin gene was clearly increased following 5-aza-dC treatment in a number of oral cancer cell tines. These results imply that an action of 5-aza-dC is separate from induction of promoter demethylation. Treatment with FR901228 resulted in a time-dependent stimulation of the re-expression of maspin mRNA as early as 4 h after treatment in the maspin downregulated cells. The re-expression of the maspin gene may contribute to the recuperation of biological functions linked to FR901228 such as an inhibitory effect on tumor angiogenesis and cell invasion. These results indicate that maspin and its target genes may be excellent leads for future studies on the potential benefits of FR901228, a HDAC inhibitor, in cancer therapy.
Digital Object Identifer:10.1016/j.oraloncology.2003.12.008
Published with permission from the copyright holder. This is the institute's copy, as published in Oral Oncology, February 2004, Volume 40, Issue 6, Pages 597-603.
Direct access to Thomson Web of Science record
Copyright © 2004 Elsevier Ltd. All rights reserved.
|Web of Sience KeyUT|